Overview of trial design
We conducted a single-center RCT using a completely randomized two-arms design to investigate whether APP would decrease the morbidity of PPCs and improve postoperative oxygenation for geriatric patients with hip fracture (Fig. 1and Fig. 2). The Standard Protocol: Items: Recommendations for Interventional Trials (SPIRIT) checklist [27] is provided as Additional file 1. All patients considered for inclusion are admitted from the emergency department to the Trauma and Orthopedic Unit of the Zhongda Hospital affiliated to Southeast University and would be operated by the same team in a fixed operating room. A designated investigator employed a 1:1 randomization system to assign patients who met the criteria to the APP group and the control group. Patients enrolled in the study will be followed for 90 PODs.
Patients would undergo a review of hematological parameters including routine blood, biochemistry, electrolyte, blood gas analysis on POD 4. Clinical pulmonary infection score (CPIS) [28] (Additional file 2) will also be calculated on POD 4. The incidence of various postoperative complications, mortality rate, and LOS during hospitalization were recorded. At the same time, the incidence of postoperative complications, especially PPCs, readmission and mortality will be calculated on POD 30 and 90, respectively. This protocol was approved by the independent ethics committee (IEC) for Clinical Research of Zhongda Hospital, Affiliated to Southeast University (2021ZDSYLL203-P01) and is registered on Chinese Clinical Trial Registry (ChiCTR2100049311). Only the head of this series of researches (YR) has the right to make the final decision to terminate the trial if any serious adverse event judged to be related to the study treatment occurs.
Primary Research Question
In geriatric patients with hip fractures, does the addition of APP to routine postoperative treatment reduce the risk of developing PPCs?
Secondary Research Question
In geriatric patients with hip fractures, does the addition of APP to routine postoperative treatment result in:
-
Improved postoperative oxygenation?
-
Shorter LOS?
-
Decreased incidence of other kinds of postoperative complications, readmission and mortality?
Hypothesis
Compared with the control group, geriatric patients with hip fractures who received postoperative APP treatment had a lower incidence of PPCs during the first 30 PODs and an improved postoperative oxygenation.
Setting And Participants
Geriatric patients (over 65 years old) presenting to the emergency department with an acute hip fracture after September 1, 2021, will be screened for eligibility and enrolled by an investigator (YG). All potentially eligible patients are admitted to Trauma and Orthopedic Unit of the Zhongda Hospital affiliated to Southeast University. Prior to admission, trauma center physicians will take the patient's medical history, risk assessment, physical examination, necessary laboratory and imaging tests.
Once confirmed to receiving surgical treatment, the research implementer (YG) will represent informed consent for participants in the study using the approved IEC Informed Consent Forms (Additional file 3). All patients will understand that depending on the randomization results, they may or may not receive a postoperative prone position. Participants in the study are voluntary, and if they refuse, their decision will not affect any other aspect of their care. Patients will have the right to learn any details of the intervention and to withdraw from the study at any point.
Inclusion criteria
Patients meeting the following criteria will be considered for eligibility:
- Aged over 65
- Informed consent and voluntary participation in a clinical trial
- Diagnosed with acute hip fracture induced by low-energy injury including intertrochanteric fracture and FNF within 14 days before admission
- In at least one of the following conditions:
- Type 2 Diabetes Mellitus (T2DM)
- Chronic lung disease such as chronic obstructive pulmonary disease
- Pre-injury activities of daily living (ADL) score < 5
- Modified British Medical Research Council (mMRC) score ≥ 2
- First result of leukocyte count > 10 × 109/L or C-reaction protein (CRP) > 15 mg/L at admission
- First result of PaO2 < 80 mmHg or SaO2 < 96% at the time of admission
- First result of hemoglobin < 100 g/L at the time of admission
- First result of serum albumin < 35 g/L at the time of admission
- Previous history of smoking and sleep apnea syndrome
- Able to remain in a prone position for at least 30 consecutive minutes
- Intertrochanteric fracture patients receiving closed reduction and internal fixation (proximal femoral locking gamma nail); FNF patients receiving posterior approach uncemented total hip arthroplasty (THA) or hemiarthroplasty (HHA) as procedure methods
Exclusion criteria
Patients meeting the following criteria will be considered for exclusion.
- With life-threatening organ dysfunction, decompression sickness or unable to disengage from guardianship or non-invasive/invasive mechanical ventilation
- With pulmonary comorbidities that included in PPCs before surgery
- With osteosarcoma, multiple myeloma, and various other pathological fractures
- With multiple fractures or injuries
- With a bilateral hip fracture
- Receiving hip revision surgery
- With history of major cardiac and pulmonary surgery
- In an immune-disorder condition caused by various causes (malignant tumors, severe autoimmune diseases, long-term hormone use, etc.)
Baseline
Baseline assessment includes, gender, age, body mass index (BMI), type of fracture, time from injury to surgery, pre-injury ADL score, mMRC score, American Society of Anesthesiologists classification and comorbidities including pulmonary disease according to the first result of thoracic computerized tomography (CT) at admission [atelectasis, pleural effusion, chronic obstructive pulmonary disease], hypertension, T2DM, coronary atherosclerotic heart disease, cognitive dysfunction, prior stroke, cerebral infarction, history of smoking and drinking, first laboratory results of arterial blood gas analysis [PaO2, PaCO2, SaO2, pH, lactic acid], routine blood test (erythrocyte count, leukocyte count, CRP, hemoglobin), biochemistry test (serum albumin, blood glucose, blood creatinine, blood urea nitrogen), electrolyte test (serum potassium, serum sodium), D-dimer, brain natriuretic peptide (BNP), time from injury to surgery, proportion of receiving surgery within 48 hours after admission, surgical procedures (closed reduction and internal fixation, THA or HHA), methods of anesthesia (general or epidural anesthesia), postoperative respiratory failure risk index [29] (Additional file 4), POP risk index [30] (Additional file 5), duration of surgery, perioperative blood transfusion volume and LOS.
Randomization and allocation
Randomization will take place once participants have signed informed consent for the procedure. SAS software 9.4 is used to generate the random table as allocation sequence by an investigator (LS) and random numbers will be assigned by envelope method. Based on random numbers, another investigator (TX) assigned patients to APP group or control group in a 1:1 ratio. Details of any planned restriction will be provided in a separate document that is unavailable to those who enroll participants or assign interventions.
Blinding
Keeping trial participants and care providers blinded is unrealistic. But neither the outcome assessors nor the data analysts are aware of the grouping. Grouping information will be represented to data analysts in the form of group A/B rather than APP group and control group. During the data analysis phase, all personal information that can be used to identify the participants will be hidden.
Intervention
After signing informed consent, participants will be enrolled and randomly assigned to either the APP group or the control group. Surgical treatment will be performed on an emergency basis upon completion of the necessary pre-operative preparations. The surgical procedures, including closed reduction and internal fixation, THA and HHA, will be decided by the chief physician (HC and YR) in trauma orthopedics. All operations will be scheduled in a fixed operating theatre and completed by the same team. Patients in the APP group will receive the prone position for at least half an hour at a time, and at least once per day for the first three consecutive PODs. The first prone position treatment each day will be guided and supervised. The frequency and duration of other spontaneous prone positions in the APP group will not be constrained. Except for this, during this period, all patients will receive the same postoperative management including postoperative oxygen inhalation (2L/min) for 6 hours, standardized nutritional support, anti-inflammatory, detumescent, analgesic, hypodermic anti-coagulant prophylaxis and regular atomization therapy. Both FNF and intertrochanteric fracture patients roll onto their broken side into a prone position. Prone position pads will be used to suspend the upper abdomen and chest to reduce intra-abdominal and intra-thoracic pressure, allowing the alveoli to expand sufficiently. If severe adverse events such as unbearable pain, suspected prosthesis dislocation or internal fixation failure, chest tightness, and difficulty breathing occur, or the patient reports that he/she cannot tolerate the supine position, the intervention should be stopped immediately. The investigator's department will treat and compensate the patient for any additional injuries resulting from APP treatment. Intervention time as an adherence quantitative indicator and the reasons for cease will be recorded in the database. Hematological parameters and chest radiography will be re-examined on the morning of POD 4. Patients will be followed up for 90 PODs through outpatient visits or telephone calls. In addition to orthopedic-related tests, they will undergo chest CT in an outpatient setting to determine if PPCs are present. The conduct of the trial will be audited weekly, independently of the investigators.
STANDARD OF DISCHARGE: 1. The x-ray shows that the position of the internal fixation/prosthesis is in place. 2. The incision is essentially healed, and no signs of infection are found. 3. No serious complications have occurred requiring continued hospitalization. 4. The serological test results and the general condition of the patient are acceptable.
Primary outcome
The primary outcome of the study will be the incidence of PPCs during the first 30 PODs. PPCs include all related diseases (atelectasis, POP, ARDS, pulmonary embolism, pleural effusion, pneumothorax, cardiogenic pulmonary edema, and bronchospasm) diagnosed anywhere within the first 30 PODs.
Secondary outcome
The secondary outcomes will be PaO2 on POD 4, the difference in PaO2 values between POD 4 and emergency visits (EV), CPIS on POD 4, LOS, other types of post-operative complications, readmission, and mortality in 90-day follow-up.
Given that FiO2 is equal to 20.9% of the breathing room air, we use PaO2 instead of P/F to reflect the patient's oxygenation capacity. On the morning of POD 4, the patient will undergo arterial blood gas analysis while inhaling room air. We anticipate that postoperative oxygenation (expressed as PaO2), will be higher in the APP group than in the control group. To minimize the impact of the baseline oxygenation capacity of different participants on the results, we use the difference in PaO2 values between POD 4 and EV to balance out this individual difference. Additional tests are required for the diagnosis of complications, such as chest CT, pulmonary and coronary CT angiography, brain CT, arterial blood gas analysis, myocardial X-ray, troponin and BNP, and will be performed as soon as suspicious symptoms such as dyspnea, chest distress, fever, cough, sputum and motor, sensory or cognitive dysfunction appear. All post-operative complications will be diagnosed following consultation with the appropriate specialist. Readmission and mortality rates within 30 or 90 PODs will be calculated separately. All serious adverse events, as well as all non-serious adverse events that are unexpected and determined to be related to the APP treatment, will be recorded in the study database and reported on request to the IEC for Clinical Research of Zhongda Hospital, Affiliated to Southeast University.